Guggenheim Starts Mineralys Therapeutics, Inc. (MLYS) at Buy
Tweet
Share
E-mailGet Alerts MLYS Hot Sheet
Price: $25.34 -1.29%
Rating Summary:
10 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Rating Summary:
10 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Join SI Premium – FREE
Guggenheim analyst Seamus Fernandez initiates coverage on Mineralys Therapeutics, Inc. (NASDAQ: MLYS) with a Buy rating and a price target of $32.00.
For an analyst ratings summary and ratings history on Mineralys Therapeutics, Inc. click here. For more ratings news on Mineralys Therapeutics, Inc. click here.
Shares of Mineralys Therapeutics, Inc. closed at $18.96 yesterday.
You May Also Be Interested In
- Chardan Assumes Rocket Pharmaceuticals (RCKT) at Buy
- Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
- Canaccord Starts Aclaris Therapeutis (ACRS) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
